Virax Biolabs Group Limited, a biotechnology company focused on diagnosing immune responses, has entered a research agreement with Emory University to advance clinical studies for its ViraxImmune platform. The collaboration involves Emory’s Center for the Advancement of Diagnostics for a Just Society (ADJUST Center) and will investigate immune profiles in individuals with long COVID, medically referred to as post-acute sequelae of SARS-CoV-2 (PASC). These studies are intended to support the regulatory progress of ViraxImmune, which is designed to deliver more detailed insights into immune system activity, particularly in chronic health conditions that conventional diagnostic tools may not fully capture.
Health Technology Insights: knownwell Expands with Second Clinic in Greater Boston
As part of this agreement, the Emory Laboratory for Innovative Assay Development (ELIAD) will manage patient recruitment, testing, and clinical data analysis. The study is expected to generate valuable data on how the immune system functions in people suffering from long-term effects of viral infections. Virax plans to use these insights to prepare for a pre-submission meeting with the U.S. Food and Drug Administration (FDA), scheduled for early September 2025. The objective of the meeting is to seek feedback from the FDA regarding the proposed use of ViraxImmune™ and to clarify the regulatory steps required for potential approval. The guidance received will help inform the design of larger U.S. clinical trials and support the company’s strategic plans for market entry.
James Foster, Chief Executive Officer of Virax Biolabs, shared his optimism about the partnership and emphasized the significance of collaborating with a respected research institution like Emory. He stated that this move represents an important milestone in proving ViraxImmune’s effectiveness in practical, clinical settings. Foster pointed out that long COVID and other post-viral syndromes continue to affect millions of people who often lack reliable diagnostic solutions. He believes that ViraxImmune™ is well-positioned to fill this gap by offering a more advanced approach to immune profiling. Additionally, the partnership strengthens the company’s pathway to the U.S. healthcare market and supports its goal of creating long-term value for investors.
Health Technology Insights: ChiroTouch Launches Rheo: The First AI Assistant Purpose-Built for Chiropractors
Dr. Wilbur A. Lam, a professor of Pediatrics and Biomedical Engineering at Emory University and Georgia Tech, and Director of the ADJUST Center, commented on the importance of better diagnostic tools for conditions like PASC. He explained that these post-viral syndromes remain underdiagnosed and are still not well understood by the broader medical community. According to Dr. Lam, the use of immune profiling technologies such as ViraxImmune™ could provide vital information about how an individual’s immune system is functioning. This information could ultimately lead to more precise diagnoses and improved treatment planning for patients living with complex, long-term health issues following viral infections.
ViraxImmune™ works by assessing T cell activity, offering a more complete picture of immune function compared to traditional antibody-based testing. This unique method allows for deeper insights into how the immune system responds over time, which can be especially helpful in identifying and managing chronic or post-viral conditions. With its collaboration with Emory underway and a regulatory meeting with the FDA on the horizon, Virax Biolabs is continuing to move forward in its mission to make immune profiling more accessible and effective for patients facing the long-term impacts of COVID-19 and other post-viral illnesses.
Health Technology Insights: Aptarro and aiHealth Partner for AI-Powered Coding Automation
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
